Zacks Investment Research Lowers Aldeyra Therapeutics (ALDX) to Hold
Zacks Investment Research downgraded shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a buy rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
A number of other research analysts have also issued reports on the company. Canaccord Genuity reaffirmed a buy rating and set a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Cantor Fitzgerald initiated coverage on Aldeyra Therapeutics in a report on Tuesday, October 24th. They set an overweight rating and a $22.00 target price on the stock. Cowen reaffirmed an outperform rating and set a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Finally, ValuEngine raised Aldeyra Therapeutics from a strong sell rating to a sell rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Aldeyra Therapeutics has an average rating of Buy and an average target price of $17.42.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. equities analysts anticipate that Aldeyra Therapeutics will post -1.39 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in ALDX. Vanguard Group Inc. boosted its position in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at $104,000. Bank of New York Mellon Corp acquired a new position in shares of Aldeyra Therapeutics in the 3rd quarter valued at $134,000. Sphera Funds Management LTD. boosted its position in shares of Aldeyra Therapeutics by 19.2% in the 3rd quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock valued at $7,518,000 after purchasing an additional 168,200 shares during the period. Finally, Perceptive Advisors LLC boosted its position in shares of Aldeyra Therapeutics by 6.9% in the 3rd quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after purchasing an additional 200,000 shares during the period. Institutional investors and hedge funds own 47.89% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.